Superiority trials in invasive aspergillosis: a harsh reality check with the IA-DUET (HOVON502) trial.

Authors :: Lamberink H
Huygens S
Aerts R
Lagrou K
van Leeuwen-Segarceanu E
Lodewyck T
Nieuwenhuizen L
Corsten MF
Moors I
Servais S
De Greef J
Hites M
Demandt A
Schauwvlieghe A
Maertens J
Rijnders B
Source :: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2024 Oct 08. Date of Electronic Publication: 2024 Oct 08.
Publication Year :: 2024
Publisher :: Ahead of Print
Abstract: The IA-DUET study aimed to compare azole-echinocandin combination with azole monotherapy for invasive aspergillosis. Recruitment was hindered by patient ineligibility, competing studies, and guidelines favoring combination therapy when azole resistance was unknown. The low IA-attributable mortality suggests future trials may benefit from cluster randomization or composite endpoints to enhance efficiency.<br /> (© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America.)

Language :: English
ISSN :: 1537-6591
Database :: MEDLINE
Journal :: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Publication Type :: Academic Journal
Accession number :: 39378343
Full Text :: https://doi.org/10.1093/cid/ciae501

Full Text Access

Tools